Skip to main content
14 search results for:

Peter Taylor 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-07-2019 | Image

    Peter C Taylor

  2. play
    08-11-2020 | Rheumatoid arthritis | Conference coverage | Video

    How will the SEAM-RA results impact clinical practice?

    Peter Taylor comments on the SEAM-RA trial, discussing how the results may inform rheumatoid arthritis treatment guidelines and the future directions for research.

  3. 08-11-2020 | Rheumatoid arthritis | Highlight | Teaser
    Expert interview

    How will the SEAM-RA results impact clinical practice?

    Peter Taylor comments on the SEAM-RA trial, discussing how the results may inform rheumatoid arthritis treatment guidelines and the future directions for research (9:06).

  4. 22-02-2021 | Ankylosing spondylitis | News | Article

    No benefit of apremilast for patients with ankylosing spondylitis

    Peter Taylor (University of Oxford, UK) and co-investigators say that ASAS20 response rates were also “generally similar” in the three groups at the 24-week follow-up, and there were no significant differences in the average change from baseline in BASFI , BASDAI , and quality of life scores at this timepoint among patients treated with apremilast 30 mg versus placebo.

  5. 08-11-2020 | ACR 2020 | Conference coverage | Article

    Better maintenance of remission with etanercept vs methotrexate monotherapy in the SEAM-RA trial

    Peter Taylor: How will the SEAM-RA results impact clinical practice?

  6. 15-07-2019 | Rheumatoid arthritis | View from the clinic | Article

    JAK inhibitors in rheumatoid arthritis

    Peter Taylor outlines the pharmacology of JAK inhibitors, and discusses their efficacy and safety profiles in patients with rheumatoid arthritis.

  7. 10-07-2020 | Rheumatoid arthritis | News | Article
    News in brief

    Addressing residual symptoms remains an unmet need in RA management

    Peter Taylor (University of Oxford, UK) and colleagues’ analysis included 53 studies investigating the nature and burden of residual disease.

  8. 16-07-2019 | Rheumatoid arthritis | Highlight | Teaser

    JAK inhibitors in rheumatoid arthritis

    Peter Taylor outlines the pharmacology of JAK inhibitors, and discusses their efficacy and safety profiles in patients with rheumatoid arthritis.

  9. 11-02-2019 | Rheumatoid arthritis | Editorial | Article

    20 years of TNF inhibitors in rheumatoid arthritis

    Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

  10. 11-02-2019 | Rheumatoid arthritis | Highlight | Teaser
    Expert opinion editorial

    20 years of TNF inhibitors in rheumatoid arthritis

    Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

  11. 26-04-2019 | Rheumatoid arthritis | News | Article

    Namilumab shows promise in phase II trial

    Peter Taylor (University of Oxford, UK) and co-investigators explain that namilumab is “an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF),” potently neutralizing the protein that is “aberrantly overproduced” in RA.

  12. 06-04-2018 | Rheumatoid arthritis | News | Article
    News in brief

    Unmet clinical needs persist in RA

    Peter Taylor (University of Oxford, UK) and co-researchers report in RMD Open that over a quarter (27%) of 1147 RA patients from France, Germany, Italy, Spain, and the UK had inadequate disease control – defined as a Disease Activity Score at 28 joints (DAS28) of more than 3.2 points – in 2014.

  13. 05-06-2017 | Rheumatoid arthritis | Feature | Article

    JAK inhibitors: The next generation of drugs for treating rheumatoid arthritis?

    This latter finding suggests that baricitinib is associated with “significant clinical improvements” compared with “a current standard-of-care treatment in this patient population,” say study author Peter Taylor (University of Oxford, UK) and colleagues.

  14. 20-02-2017 | Rheumatoid arthritis | News | Article

    Baricitinib shows promise in patients with RA

    Participants received the study drug in addition to background treatment with methotrexate, “a context in which adalimumab has proved to be most efficacious,” report researcher Peter Taylor (University of Oxford, UK) and colleagues.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.